ZYTIGA Drug Patent Profile

When do Zytiga patents expire, and when can generic versions of Zytiga launch?

Zytiga is a drug marketed by Janssen Biotech and is included in one NDA.

The generic ingredient in ZYTIGA is abiraterone acetate. There are twenty-five drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the abiraterone acetate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zytiga

A generic version of ZYTIGA was approved as abiraterone acetate by APOTEX on October 31^st, 2018.

Summary for ZYTIGA

US Patents:	0
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ZYTIGA

Paragraph IV (Patent) Challenges for ZYTIGA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ZYTIGA	Tablets	abiraterone acetate	500 mg	202379	1	2017-08-23
ZYTIGA	Tablets	abiraterone acetate	250 mg	202379	13	2015-04-28

US Patents and Regulatory Information for ZYTIGA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Biotech	ZYTIGA	abiraterone acetate	TABLET;ORAL	202379-001	Apr 28, 2011	AB	RX	Yes	No
Janssen Biotech	ZYTIGA	abiraterone acetate	TABLET;ORAL	202379-002	Apr 14, 2017	AB	RX	Yes	Yes

International Patents for ZYTIGA

See the table below for patents covering ZYTIGA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	7661894
New Zealand	249911	17-(3-PYRIDYL) SUBSTITUTED STEROIDS AND USE IN PHARMACEUTICAL COMPOSITIONS
Japan	2742331
Australia	2017201764	Methods and compositions for treating cancer
United Kingdom	9419139

Supplementary Protection Certificates for ZYTIGA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0633893	11C0055	France		PRODUCT NAME: ABIRATERONE, SES SELS D'ADDITION D'ACIDE ET 3-ESTERS, EN PARTICULIER ACETATE D'ABIRATERONE; REGISTRATION NO/DATE: EU/1/11/714/001 20110905
0633893	C00633893/01	Switzerland		PRODUCT NAME: ABIRATERONI ACETAS; REGISTRATION NUMBER/DATE: SWISSMEDIC 62084 20.09.2011
3490560	LUC50015	Luxembourg		PRODUCT NAME: NIRAPARIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF IN PARTICULAR NIRAPARIB TOSYLATE IN PARTICULAR NIRAPARIB TOSYLATE MONOHYDRATE, OPTIONALLY IN COMBINATION WITH ABIRATERONE IN PARTICULAR ABIRATERONE ACETATE; AUTHORISATION NUMBER AND DATE: EU/1/23/1722 20230420
3490560	CA 2025 00023	Denmark		PRODUCT NAME: NIRAPARIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF IN PARTICULAR NIRAPARIB TOSYLATE IN PARTICU-LAR NIRAPARIB TOSYLATE MONOHYDRATE, OPTIONALLY IN COMBINATION WITH ABIRATERONE IN PARTICULAR ABI-RATERONE ACETATE; REG. NO/DATE: EU/1/23/1722 20230420
0633893	CA 2011 00035	Denmark

Investment Scenario and Fundamentals Analysis for ZYTIGA (Abiraterone Acetate)

Last updated: February 20, 2026

What is the current market position of ZYTIGA?

ZYTIGA (abiraterone acetate) is an androgen biosynthesis inhibitor developed by Janssen Pharmaceuticals for the treatment of prostate cancer, specifically metastatic castration-resistant prostate cancer (mCRPC). It gained FDA approval in 2011 and expanded indications over subsequent years, including earlier stages of disease.

Sales Revenue Overview:

• 2022 global sales: approximately $1.4 billion (Janssen Annual Report 2022).
• Revenue declined slightly from peak sales of $1.7 billion in 2018 due to patent expiry and increased competition.

Market Share:

• Dominates the mCRPC space, with an estimated 60% market penetration as of 2022.
• Competitors include Zelboraf, Erleada (apalutamide), and relugolix.

How do the drug’s fundamentals influence investment viability?

1. Patent and Exclusivity:

   • Patent expiry in 2027 in the US; generic versions could undermine revenues.
   • Patent life extension strategies include formulation patents and potential new indications.

2. Regulatory Approvals and Approvals in New Indications:

   • FDA-approved for mCRPC.
   • Under review for earlier-line metastatic hormone-sensitive prostate cancer (mHSPC).
   • European Medicines Agency (EMA) approval in 2012, with ongoing indications expansions.

3. Market Dynamics and Growth Drivers:

   • Increasing prevalence: prostate cancer affects over 174,000 men annually in the US.
   • Aging populations in developed markets sustain demand.
   • Adoption of earlier treatment lines enhances future growth prospects.

4. Pipeline and Line Extensions:

   • Trials ongoing for combinations with immunotherapies.
   • Investigating use in breast cancer and other cancers.
   • Potential for new indications to extend patent life and revenue stream.

5. Pricing and Reimbursement:

   • Pricing remains high in the US (~$13,000 per month), influencing margins.
   • Reimbursement relies heavily on favorable insurance coverage, which is generally stable for prostate cancer treatments.

6. Manufacturing and Supply Chain:

   • Manufacturing controlled by Janssen, with established supply chains.
   • Risk factors include potential supply disruptions and biosimilar competition post-patent expiry.

What are the key financial metrics and risks?

Metric	2022	Notes
Revenue	$1.4 billion	Slight decline from 2018 peak
Operating Margin	Approx. 45%	Reflects pricing power and patent exclusivity
R&D Spending	~$300 million	Focused on pipeline expansion
Patent Expiry	2027 (US)	Major risk region; patent extensions possible
Market Penetration in USA	60%	Competitive environment influences growth

Risks:

• Patent expiration leading to generic competition.
• Slow approval or failure in new indications.
• Increased competition from novel therapies.
• Pricing pressure and reimbursement changes.

Investment outlook based on fundamentals

• Short-term: Stabilization expected, with sales plateauing ahead of patent expiry.
• Mid-term: Revenue erosion likely as generics enter the market, unless extended through new indications or combinations.
• Long-term: Potential upside from pipeline successes and new indications. Price appreciation depends on pipeline progresses and global adoption.

Key Takeaways

• ZYTIGA holds a strong market position in prostate cancer treatment, with consistent revenues driven by existing indications and high market penetration.
• Patent expiry in 2027 poses a significant risk, potentially leading to revenue decline unless offset by pipeline developments.
• Ongoing trials for earlier treatment settings and combination therapies could extend product lifecycle and revenue.
• Competitive pressures and reimbursement dynamics influence future growth prospects.
• Investors should weigh near-term stability against long-term risks from generic competition and pipeline success.

FAQs

1. When will ZYTIGA face generic competition?
Patent expiry in the US is scheduled for 2027, after which generics are expected to enter the market, significantly impacting revenues.

2. Are there indications that could extend ZYTIGA’s patent?
Yes. Filing for additional indications like mHSPC and novel combinations may provide patent extensions or new revenue streams.

3. How does ZYTIGA compare to its competitors?
It has maintained around 60% market share due to proven efficacy and strong clinical support, though newer agents like Erleada challenge its dominance.

4. What are the key risks and rewards of investing in ZYTIGA?
Risk includes revenue decline post-patent expiry and emerging competitors. Rewards hinge on pipeline success and market expansion in new indications.

5. How does the prostate cancer market look globally?
The market is growing due to aging populations and increased screening, with the US being the largest market. International expansion remains strategic.

---

References

[1] Janssen Global. (2022). Annual Report 2022.
[2] U.S. Food and Drug Administration. (2011). ZYTIGA approval documentation.
[3] MarketWatch. (2022). Prostate cancer drug market analysis.
[4] European Medicines Agency. (2012). ZYTIGA approval summary.